Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Those that grow and spread slowly are described as ‘indolent’, one of the most common types of which is follicular lymphoma. About one-fifth of new cases of non-Hodgkin lymphoma are diagnosed ...

which began a priority review at the FDA last October as a third-line treatment for DLBCL and for follicular lymphoma (FL), another form of non-Hodgkin lymphoma (NHL). The bispecific antibodies ...

For evaluating response to treatment for follicular lymphoma, computed tomography (CT) has been considered the gold standard, and most clinical studies and trials have used CT as a tool for ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.